137 related articles for article (PubMed ID: 26916814)
1. Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib.
Shumilov E; Wulf G; Ströbel P; Hasenkamp J; Hellige N; Bleckmann A; Haase D; Braulke F; Jung W; Schanz J; Binder M; Trümper L; Bacher U
Leuk Lymphoma; 2016 Oct; 57(10):2476-80. PubMed ID: 26916814
[No Abstract] [Full Text] [Related]
2. [Cryptococcal meningitis in the treatment of CLL with ibrutinib: a case report and literature review].
Zhang H; Zhang XH; Chen P; Li BZ
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):428-430. PubMed ID: 32536143
[No Abstract] [Full Text] [Related]
3. Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia.
Schliffke S; Akyüz N; Ford CT; Mährle T; Thenhausen T; Krohn-Grimberghe A; Knop S; Bokemeyer C; Binder M
Leukemia; 2016 Nov; 30(11):2232-2234. PubMed ID: 27220665
[No Abstract] [Full Text] [Related]
4. HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.
Innocenti I; Morelli F; Autore F; Corbingi A; Pasquale R; Sorà F; Pompili M; Laurenti L
Leuk Lymphoma; 2019 May; 60(5):1340-1342. PubMed ID: 30730231
[No Abstract] [Full Text] [Related]
5. Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison.
Andrasiak I; Rybka J; Knopinska-Posluszny W; Wrobel T
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):268-273. PubMed ID: 28395851
[TBL] [Abstract][Full Text] [Related]
6. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
Lee A; Sandhu S; Imlay-Gillespie L; Mulligan S; Shumack S
Australas J Dermatol; 2017 Nov; 58(4):e240-e242. PubMed ID: 28295171
[TBL] [Abstract][Full Text] [Related]
7. Life after ibrutinib? A new unmet need in CLL.
Pinilla-Ibarz J; Chavez JC
Blood; 2015 Mar; 125(13):2013-4. PubMed ID: 25814485
[TBL] [Abstract][Full Text] [Related]
8. Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.
Williams AM; Baran AM; Schaffer M; Bushart J; Rich L; Moore J; Barr PM; Zent CS
Am J Hematol; 2020 Jan; 95(1):E16-E18. PubMed ID: 31621100
[No Abstract] [Full Text] [Related]
9. Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion.
Cavazzini F; Lista E; Quaglia FM; Formigaro L; Cavallari M; Martinelli S; Rigolin GM; Foà R; Cuneo A
Leuk Lymphoma; 2016 Nov; 57(11):2685-8. PubMed ID: 26999572
[No Abstract] [Full Text] [Related]
10. Spuriously low lymphocyte count associated with pseudoerythroblastemia in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Robier C; Beham-Schmid C; Neubauer M
Clin Chem Lab Med; 2018 Apr; 56(5):e112-e114. PubMed ID: 29252190
[No Abstract] [Full Text] [Related]
11. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
Goldschmidt N; Rund D
Leuk Lymphoma; 2017 Feb; 58(2):498-500. PubMed ID: 27756158
[No Abstract] [Full Text] [Related]
12. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.
Strati P; Schlette EJ; Solis Soto LM; Duenas DE; Sivina M; Kim E; Keating MJ; Wierda WG; Ferrajoli A; Kantarjian H; Estrov Z; Jain N; Thompson PA; Wistuba II; Burger JA
Blood; 2020 Feb; 135(7):510-513. PubMed ID: 31895947
[No Abstract] [Full Text] [Related]
13. High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
Teh BW; Chui W; Handunnetti S; Tam C; Worth LJ; Thursky KA; Slavin MA
Leuk Lymphoma; 2019 Jun; 60(6):1572-1575. PubMed ID: 30632838
[No Abstract] [Full Text] [Related]
14. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
Kreiniz N; Bejar J; Polliack A; Tadmor T
Hematol Oncol; 2018 Feb; 36(1):349-354. PubMed ID: 28156016
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.
Montillo M; O'Brien S; Tedeschi A; Byrd JC; Dearden C; Gill D; Brown JR; Barrientos JC; Mulligan SP; Furman RR; Cymbalista F; Plascencia C; Chang S; Hsu E; James DF; Hillmen P
Blood Cancer J; 2017 Feb; 7(2):e524. PubMed ID: 28157216
[No Abstract] [Full Text] [Related]
16. Is HBV prophylaxis required during CLL treatment with ibrutinib?
Tedeschi A; Frustaci AM; Mazzucchelli M; Cairoli R; Montillo M
Leuk Lymphoma; 2017 Dec; 58(12):2966-2968. PubMed ID: 28535112
[No Abstract] [Full Text] [Related]
17. Ibrutinib: targeting the hidden CLL.
Awan FT
Blood; 2014 May; 123(21):3215-6. PubMed ID: 24855190
[No Abstract] [Full Text] [Related]
18. Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.
Tucker DL; Mihailescu L; Riordan R; Rule S
Br J Haematol; 2017 Jul; 178(1):153-155. PubMed ID: 27172457
[No Abstract] [Full Text] [Related]
19. Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib.
Boudin L; Patient M; Tsitsi Nding Tsogou P; Roméo E; Bladé JS; de Jauréguiberry JP
Bull Cancer; 2019 Jan; 106(1):84-85. PubMed ID: 30579570
[No Abstract] [Full Text] [Related]
20. Recovery of full donor chimerism with ibrutinib therapy in relapsed CLL after allogeneic stem cell transplantation.
Quinquenel A; Sicre de Fontbrune F; Durot E; Pannetier M; Michonneau D; Socié G; Delmer A; Peffault De Latour R
Br J Haematol; 2017 Mar; 176(6):997-999. PubMed ID: 26991435
[No Abstract] [Full Text] [Related]
[Next] [New Search]
